Jan Mikkelsen - Ascendis Pharma CEO
| ASND Stock | USD 142.10 1.93 1.38% |
CEO
Mr. Jan Moeller Mikkelsen serves as President, Chief Executive Officer, Director of Ascendis Pharma AS. He cofounded Ascendis Pharma and has served as our President and Chief Executive Officer and as a member of our board of directors since December 2007. From 2002 to 2006, Mr. Mikkelsen served as President and Chief Executive Officer of LifeCycle Pharma AS, now known as Veloxis Pharmaceuticals AS, a publicly traded biotechnology company. From 2000 to 2002, Mr. Mikkelsen served as CoPresident and subsequently as President of the Pharmaceutical Division of Maxygen, Inc., a protein pharmaceuticals business. Mr. Mikkelsen cofounded ProFound Pharma AS, a biopharmaceutical company that was later acquired by Maxygen, Inc., and he served as CoChief Executive Officer from 1999 to 2000. Prior to founding ProFound, Mr. Mikkelsen held various positions at Novo Nordisk AS, a global healthcare company, and served as its Vice President of protein discovery from 1991 to 1999. Mr. Mikkelsen currently serves as a member of the advisory board of Inspirion Delivery Technologies, a specialty pharmaceutical company. Mr. Mikkelsen is Cand. Scient. in Biochemistry from the University of Odense. since 2007.
| Age | 64 |
| Tenure | 17 years |
| Address | Tuborg Boulevard 12, Hellerup, Denmark, 2900 |
| Phone | 45 70 22 22 44 |
| Web | https://ascendispharma.com |
Ascendis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2973) % which means that it has lost $0.2973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1843) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.47, whereas Return On Tangible Assets are forecasted to decline to (0.62). At present, Ascendis Pharma's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 374.1 M, whereas Non Current Assets Total are forecasted to decline to about 79.4 M.Similar Executives
| Found 11 records | CEO Age | ||
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Roger Jeffs | United Therapeutics | 53 | |
| Jeffrey Albers | Blueprint Medicines Corp | 46 | |
| Chen Schor | Madrigal Pharmaceuticals | 41 | |
| Andrew MD | Akero Therapeutics | 57 | |
| Scott Struthers | Crinetics Pharmaceuticals | 62 | |
| Robert Coffin | Replimune Group | 59 | |
| William Sibold | Madrigal Pharmaceuticals | 58 | |
| Cedric Francois | Apellis Pharmaceuticals | 45 | |
| Raju Mohan | Ventyx Biosciences | 66 | |
| James Porter | Nuvalent | 48 | |
Management Performance
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.3 |
Ascendis Pharma AS Leadership Team
Elected by the shareholders, the Ascendis Pharma's board of directors comprises two types of representatives: Ascendis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascendis. The board's role is to monitor Ascendis Pharma's management team and ensure that shareholders' interests are well served. Ascendis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascendis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Soloway, CFO, Sr. VP and Member of Executive Board | ||
| Martin Auster, Senior Vice President | ||
| Michael LLM, Chief VP | ||
| Jonathan Silverstein, Director | ||
| Scott Holmes, Head Endocrinology | ||
| Timothy Lee, Director Relations | ||
| Jens Okkels, VP Devel | ||
| Flemming Jensen, Senior Vice President Product Supply | ||
| Harald Rau, Chief Scientific Officer, Sr. VP and Member of Executive Board | ||
| Mads Bodenhoff, Senior Officer | ||
| Kennett Sprogoee, Senior Vice President Product Innovation | ||
| Lotte Sonderbjerg, Sr Officer | ||
| Peter Rasmussen, Principal Accounting Officer and VP of Fin. | ||
| Kennett Sprogoe, Executive Development | ||
| Edwin Graaf, Director | ||
| Michael Mayer, Director | ||
| Grethe Rasmussen, Sr. VP of Product Devel. and Member of Executive Board | ||
| Rafaele Tordjman, Director | ||
| James Healy, Director | ||
| Birgitte MD, Sr Affairs | ||
| Stina MD, Executive Oncology | ||
| Nyssa Noyola, Vice Management | ||
| Albert Cha, Director | ||
| Martin Olin, Director | ||
| Lotte Soenderbjerg, Senior Vice President Chief Administrative Officer, Managing Director of Ascendis Pharma GmbH | ||
| Michael Jensen, Chairman of the Board, Senior Vice President General Counsel | ||
| Rafale Tordjman, Director | ||
| Scott Smith, CFO, Senior Vice President | ||
| Jonathan Leff, Chief Medical Officer | ||
| Jan Mikkelsen, CEO and President Member of Executive Board and Executive Director | ||
| Joseph Kelly, Head Endocrinology |
Ascendis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascendis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (1.81) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 8.18 B | ||||
| Shares Outstanding | 56.61 M | ||||
| Shares Owned By Insiders | 0.76 % | ||||
| Shares Owned By Institutions | 99.24 % | ||||
| Number Of Shares Shorted | 3.35 M | ||||
| Price To Earning | (9.10) X |
Ascendis Pharma Investors Sentiment
The influence of Ascendis Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Ascendis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Ascendis Pharma's public news can be used to forecast risks associated with an investment in Ascendis. The trend in average sentiment can be used to explain how an investor holding Ascendis can time the market purely based on public headlines and social activities around Ascendis Pharma AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ascendis Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ascendis Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Ascendis Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Ascendis Pharma.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ascendis Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ascendis Pharma's short interest history, or implied volatility extrapolated from Ascendis Pharma options trading.
Pair Trading with Ascendis Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ascendis Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascendis Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Ascendis Stock
| 0.65 | MRK | Merck Company Earnings Call This Week | PairCorr |
Moving against Ascendis Stock
| 0.45 | EVO | Evotec SE ADR Earnings Call Tomorrow | PairCorr |
| 0.44 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
The ability to find closely correlated positions to Ascendis Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ascendis Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ascendis Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ascendis Pharma AS to buy it.
The correlation of Ascendis Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ascendis Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ascendis Pharma AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ascendis Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Ascendis Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.13) | Revenue Per Share 4.739 | Quarterly Revenue Growth 5.014 | Return On Assets (0.30) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.